Catherine A Shu1, Malcolm C Pike2, Anjali R Jotwani3, Tara M Friebel4, Robert A Soslow5, Douglas A Levine6, Katherine L Nathanson7, Jason A Konner8, Angela G Arnold3, Faina Bogomolniy6, Fanny Dao6, Narciso Olvera6, Elizabeth K Bancroft9, Deborah J Goldfrank6, Zsofia K Stadler3, Mark E Robson10, Carol L Brown6, Mario M Leitao6, Nadeem R Abu-Rustum6, Carol A Aghajanian8, Joanne L Blum11, Susan L Neuhausen12, Judy E Garber4, Mary B Daly13, Claudine Isaacs14, Rosalind A Eeles9, Patricia A Ganz15, Richard R Barakat6, Kenneth Offit3, Susan M Domchek7, Timothy R Rebbeck4, Noah D Kauff16. 1. Division of Hematology-Oncology, Columbia University Medical Center, New York, New York. 2. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York. 3. Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 4. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. 5. Gynecologic Pathology Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. 6. Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. 7. Basser Center for BRCA and Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia. 8. Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 9. Institute of Cancer Research, Royal Marsden National Health Service Foundation Trust, London, England. 10. Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York10Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 11. Baylor-Charles A. Sammons Cancer Center, Texas Oncology, Dallas. 12. Department of Population Sciences, Beckman Research Institute, City of Hope National Medical Center, Duarte, California. 13. Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, Pennsylvania. 14. Department of Oncology and Medicine, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC. 15. UCLA Schools of Public Health and Medicine, University of California, Los Angeles16Center for Cancer Prevention and Control Research, University of California, Los Angeles17Jonsson Comprehensive Cancer Center, University of California, Los Angeles. 16. Clinical Cancer Genetics Program, Duke Cancer Institute, Duke University Health System, Durham, North Carolina.
Abstract
IMPORTANCE: The link between BRCA mutations and uterine cancer is unclear. Therefore, although risk-reducing salpingo-oophorectomy (RRSO) is standard treatment among women with BRCA mutations (BRCA+ women), the role of concomitant hysterectomy is controversial. OBJECTIVE: To determine the risk for uterine cancer and distribution of specific histologic subtypes in BRCA+ women after RRSO without hysterectomy. DESIGN, SETTING, AND PARTICIPANTS: This multicenter prospective cohort study included 1083 women with a deleterious BRCA1 or BRCA2 mutation identified from January 1, 1995, to December 31, 2011, at 9 academic medical centers in the United States and the United Kingdom who underwent RRSO without a prior or concomitant hysterectomy. Of these, 627 participants were BRCA1+; 453, BRCA2+; and 3, both. Participants were prospectively followed up for a median 5.1 (interquartile range [IQR], 3.0-8.4) years after ascertainment, BRCA testing, or RRSO (whichever occurred last). Follow up data available through October 14, 2014, were included in the analyses. Censoring occurred at uterine cancer diagnosis, hysterectomy, last follow-up, or death. New cancers were categorized by histologic subtype, and available tumors were analyzed for loss of the wild-type BRCA gene and/or protein expression. MAIN OUTCOMES AND MEASURES: Incidence of uterine corpus cancer in BRCA+ women who underwent RRSO without hysterectomy compared with rates expected from the Surveillance, Epidemiology, and End Results database. RESULTS: Among the 1083 women women who underwent RRSO without hysterectomy at a median age 45.6 (IQR: 40.9 - 52.5), 8 incident uterine cancers were observed (4.3 expected; observed to expected [O:E] ratio, 1.9; 95% CI, 0.8-3.7; P = .09). No increased risk for endometrioid endometrial carcinoma or sarcoma was found after stratifying by subtype. Five serous and/or serous-like (serous/serous-like) endometrial carcinomas were observed (4 BRCA1+ and 1 BRCA2+) 7.2 to 12.9 years after RRSO (BRCA1: 0.18 expected [O:E ratio, 22.2; 95% CI, 6.1-56.9; P < .001]; BRCA2: 0.16 expected [O:E ratio, 6.4; 95% CI, 0.2-35.5; P = .15]). Tumor analyses confirmed loss of the wild-type BRCA1 gene and/or protein expression in all 3 available serous/serous-like BRCA1+ tumors. CONCLUSIONS AND RELEVANCE: Although the overall risk for uterine cancer after RRSO was not increased, the risk for serous/serous-like endometrial carcinoma was increased in BRCA1+ women. This risk should be considered when discussing the advantages and risks of hysterectomy at the time of RRSO in BRCA1+ women.
IMPORTANCE: The link between BRCA mutations and uterine cancer is unclear. Therefore, although risk-reducing salpingo-oophorectomy (RRSO) is standard treatment among women with BRCA mutations (BRCA+ women), the role of concomitant hysterectomy is controversial. OBJECTIVE: To determine the risk for uterine cancer and distribution of specific histologic subtypes in BRCA+ women after RRSO without hysterectomy. DESIGN, SETTING, AND PARTICIPANTS: This multicenter prospective cohort study included 1083 women with a deleterious BRCA1 or BRCA2 mutation identified from January 1, 1995, to December 31, 2011, at 9 academic medical centers in the United States and the United Kingdom who underwent RRSO without a prior or concomitant hysterectomy. Of these, 627 participants were BRCA1+; 453, BRCA2+; and 3, both. Participants were prospectively followed up for a median 5.1 (interquartile range [IQR], 3.0-8.4) years after ascertainment, BRCA testing, or RRSO (whichever occurred last). Follow up data available through October 14, 2014, were included in the analyses. Censoring occurred at uterine cancer diagnosis, hysterectomy, last follow-up, or death. New cancers were categorized by histologic subtype, and available tumors were analyzed for loss of the wild-type BRCA gene and/or protein expression. MAIN OUTCOMES AND MEASURES: Incidence of uterine corpus cancer in BRCA+ women who underwent RRSO without hysterectomy compared with rates expected from the Surveillance, Epidemiology, and End Results database. RESULTS: Among the 1083 women women who underwent RRSO without hysterectomy at a median age 45.6 (IQR: 40.9 - 52.5), 8 incident uterine cancers were observed (4.3 expected; observed to expected [O:E] ratio, 1.9; 95% CI, 0.8-3.7; P = .09). No increased risk for endometrioid endometrial carcinoma or sarcoma was found after stratifying by subtype. Five serous and/or serous-like (serous/serous-like) endometrial carcinomas were observed (4 BRCA1+ and 1 BRCA2+) 7.2 to 12.9 years after RRSO (BRCA1: 0.18 expected [O:E ratio, 22.2; 95% CI, 6.1-56.9; P < .001]; BRCA2: 0.16 expected [O:E ratio, 6.4; 95% CI, 0.2-35.5; P = .15]). Tumor analyses confirmed loss of the wild-type BRCA1 gene and/or protein expression in all 3 available serous/serous-like BRCA1+ tumors. CONCLUSIONS AND RELEVANCE: Although the overall risk for uterine cancer after RRSO was not increased, the risk for serous/serous-like endometrial carcinoma was increased in BRCA1+ women. This risk should be considered when discussing the advantages and risks of hysterectomy at the time of RRSO in BRCA1+ women.
Authors: Susan M Domchek; Tara M Friebel; Christian F Singer; D Gareth Evans; Henry T Lynch; Claudine Isaacs; Judy E Garber; Susan L Neuhausen; Ellen Matloff; Rosalind Eeles; Gabriella Pichert; Laura Van t'veer; Nadine Tung; Jeffrey N Weitzel; Fergus J Couch; Wendy S Rubinstein; Patricia A Ganz; Mary B Daly; Olufunmilayo I Olopade; Gail Tomlinson; Joellen Schildkraut; Joanne L Blum; Timothy R Rebbeck Journal: JAMA Date: 2010-09-01 Impact factor: 56.272
Authors: D A Levine; O Lin; R R Barakat; M E Robson; D McDermott; L Cohen; J Satagopan; K Offit; J Boyd Journal: Gynecol Oncol Date: 2001-03 Impact factor: 5.482
Authors: Noah D Kauff; Jaya M Satagopan; Mark E Robson; Lauren Scheuer; Martee Hensley; Clifford A Hudis; Nathan A Ellis; Jeff Boyd; Patrick I Borgen; Richard R Barakat; Larry Norton; Mercedes Castiel; Khedoudja Nafa; Kenneth Offit Journal: N Engl J Med Date: 2002-05-20 Impact factor: 91.245
Authors: Jason D Wright; Cande V Ananth; Sharyn N Lewin; William M Burke; Yu-Shiang Lu; Alfred I Neugut; Thomas J Herzog; Dawn L Hershman Journal: JAMA Date: 2013-02-20 Impact factor: 56.272
Authors: Susan M Domchek; Tara M Friebel; Susan L Neuhausen; Theresa Wagner; Gareth Evans; Claudine Isaacs; Judy E Garber; Mary B Daly; Rosalind Eeles; Ellen Matloff; Gail E Tomlinson; Laura Van't Veer; Henry T Lynch; Olufunmilayo I Olopade; Barbara L Weber; Timothy R Rebbeck Journal: Lancet Oncol Date: 2006-03 Impact factor: 41.316
Authors: Beverly Long; Jenna Lilyquist; Amy Weaver; Chunling Hu; Rohan Gnanaolivu; Kun Y Lee; Steven N Hart; Eric C Polley; Jamie N Bakkum-Gamez; Fergus J Couch; Sean C Dowdy Journal: Gynecol Oncol Date: 2018-10-26 Impact factor: 5.482
Authors: Kathryn A Mills; Tanvi V Joshi; Lindsay West; Michelle Kuznicki; Laura Kent; Alexis N Hokenstad; James C Cripe; Candice Woolfolk; Leigha Senter; Jamie N Bakkum-Gamez; Robert M Wenham; David E Cohn; Victoria Bae-Jump; Premal H Thaker Journal: Gynecol Oncol Date: 2020-03-03 Impact factor: 5.482
Authors: George U Eleje; Ahizechukwu C Eke; Ifeanyichukwu U Ezebialu; Joseph I Ikechebelu; Emmanuel O Ugwu; Onyinye O Okonkwo Journal: Cochrane Database Syst Rev Date: 2018-08-24